We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed at $59.20 in the latest trading session, marking a +2.65% move from the prior day. The stock's change was more than the S&P 500's daily gain of 2.51%. At the same time, the Dow added 2.85%, and the tech-heavy Nasdaq gained 2.8%.
Prior to today's trading, shares of the biopharmaceutical company had lost 4.09% was narrower than the Medical sector's loss of 5.12% and lagged the S&P 500's loss of 1.66%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. The company is expected to report EPS of $1.46, down 18.89% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $10.86 billion, reflecting a 3.02% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.26 per share and revenue of $47.02 billion, indicating changes of +1.79% and -2.43%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Bristol Myers Squibb is holding a Forward P/E ratio of 9.21. This denotes a discount relative to the industry average Forward P/E of 20.4.
It is also worth noting that BMY currently has a PEG ratio of 0.16. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
Bristol Myers Squibb (BMY - Free Report) closed at $59.20 in the latest trading session, marking a +2.65% move from the prior day. The stock's change was more than the S&P 500's daily gain of 2.51%. At the same time, the Dow added 2.85%, and the tech-heavy Nasdaq gained 2.8%.
Prior to today's trading, shares of the biopharmaceutical company had lost 4.09% was narrower than the Medical sector's loss of 5.12% and lagged the S&P 500's loss of 1.66%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. The company is expected to report EPS of $1.46, down 18.89% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $10.86 billion, reflecting a 3.02% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.26 per share and revenue of $47.02 billion, indicating changes of +1.79% and -2.43%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Bristol Myers Squibb is holding a Forward P/E ratio of 9.21. This denotes a discount relative to the industry average Forward P/E of 20.4.
It is also worth noting that BMY currently has a PEG ratio of 0.16. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.